DECRYPTION – Present for twenty years in the country, he highlights his management methods and his successes at But, Socotec, Spie and even Rexel.
In just a few days, he went from shadow to light. Since it was chosen by Sanofi to take control (50% or more) of its subsidiary Opella, manufacturer of Doliprane, the American investment fund Clayton, Dubilier & Rice, LLC (CD&R) has been in the spotlight . It’s not his habit. Although it is one of the pioneers of investment in unlisted companies with leverage (LBO), with KKR and Blackstone, the fund created in New York in 1978 cultivates discretion. Its strategy differs from that of large investment companies, which have embarked on a race for size in recent years. « It’s a human-sized background »points out someone close to the fund. CD&R manages 57 billion dollars in assets, an amount incommensurate with its historic American competitors, which are much more diversified: KKR manages 600 billion dollars and Blackstone (created in 1985), 1,000 billion…
This article is reserved for subscribers. You have 80% left to discover.
Do you want to read more?
Unlock all items immediately. No commitment.
Already subscribed? Log in
